open access
Effect of combined action of doxorubicin and calcifediol on MCF-7 breast cancer cells
, 1, 2, 2
Affiliations- Students research group of Cell Biology and Ultrastructure at Department of Histology and Embryology, Nicolaus Copernicus University in Torun, Collegium Medicum in Bydgoszcz
- Department of Histology and Embryology, Nicolaus Copernicus University in Torun, Faculty of Medicine, Collegium Medicum in Bydgoszcz
open access
Abstract
Introduction: Breast cancer is one of the most common cancers in women. Current recommendations for combination therapy in patients with breast cancer are still being developed and new therapies with greater success are sought. A relatively new approach is the administration of cytostatics in combination with vitamins. Hence, the study aimed to clarify whether the combination of calcifediol [25(OH)D3] with doxorubicin affects the response of the MCF-7 breast cancer cell line to the cytostatic.
Material and methods: In the MCF-7 cell line, the authors assessed cytotoxicity using the MTT assay, analysed the cell cycle and cell death mechanism using flow cytometry, and examined the structure of the cytoskeleton and cell morphology.
Results: The results showed that doxorubicin in combination with calcifediol in a 1:1 ratio showed a synergistic effect resulting in a dose-dependent decrease in cell survival. Further studies have shown that this is due to the pro-apoptotic and necrotic effects of the combination of these compounds. There were also changes in the organization of the cytoskeleton and cell morphology. In addition, features of entosis were noted in MCF-7 cells.
Conclusion: The synergistic effect of doxorubicin and calcifediol significantly reduced the viability of MCF-7 breast cancer cells. Inducing the desired effect by lowering the cytostatic dose is of great clinical importance, taking into account the cardiotoxicity of doxorubicin. Another very interesting aspect is the entosis process induced in the present research, which may have a dual nature.
Abstract
Introduction: Breast cancer is one of the most common cancers in women. Current recommendations for combination therapy in patients with breast cancer are still being developed and new therapies with greater success are sought. A relatively new approach is the administration of cytostatics in combination with vitamins. Hence, the study aimed to clarify whether the combination of calcifediol [25(OH)D3] with doxorubicin affects the response of the MCF-7 breast cancer cell line to the cytostatic.
Material and methods: In the MCF-7 cell line, the authors assessed cytotoxicity using the MTT assay, analysed the cell cycle and cell death mechanism using flow cytometry, and examined the structure of the cytoskeleton and cell morphology.
Results: The results showed that doxorubicin in combination with calcifediol in a 1:1 ratio showed a synergistic effect resulting in a dose-dependent decrease in cell survival. Further studies have shown that this is due to the pro-apoptotic and necrotic effects of the combination of these compounds. There were also changes in the organization of the cytoskeleton and cell morphology. In addition, features of entosis were noted in MCF-7 cells.
Conclusion: The synergistic effect of doxorubicin and calcifediol significantly reduced the viability of MCF-7 breast cancer cells. Inducing the desired effect by lowering the cytostatic dose is of great clinical importance, taking into account the cardiotoxicity of doxorubicin. Another very interesting aspect is the entosis process induced in the present research, which may have a dual nature.
Keywords
breast cancer, doxorubicin, calcifediol, synergistic effect
About this articleTitle
Effect of combined action of doxorubicin and calcifediol on MCF-7 breast cancer cells
Journal
Issue
Article type
Original article
Pages
242-250
Published online
2023-08-22
Page views
264
Article views/downloads
293
DOI
Bibliographic record
Medical Research Journal 2023;8(3):242-250.
Keywords
breast cancer
doxorubicin
calcifediol
synergistic effect
Authors
Oliwia Abramczyk
Sylwia Stawieraj
Agnieszka Mlicka
Wioletta Zielińska
Paweł Niewiadomski
Marta Hałas-Wiśniewska
Magdalena Izdebska
References (27)- Zhang YN, Xia KR, Li CY, et al. Review of Breast Cancer Pathologigcal Image Processing. Biomed Res Int. 2021; 2021: 1994764.
- Burzyńska M, Maniecka-Bryła I, Pikala M. Trends of mortality due to breast cancer in Poland, 2000-2016. BMC Public Health. 2020; 20(1): 120.
- Ahmadpour ST, Desquiret-Dumas V, Yikilmaz U, et al. Doxorubicin-Induced Autophagolysosome Formation Is Partly Prevented by Mitochondrial ROS Elimination in DOX-Resistant Breast Cancer Cells. Int J Mol Sci. 2021; 22(17).
- Brakta S, Diamond JS, Al-Hendy A, et al. Role of vitamin D in uterine fibroid biology. Fertil Steril. 2015; 104(3): 698–706.
- Trump DL, Aragon-Ching JB. Vitamin D in prostate cancer. Asian J Androl. 2018; 20(3): 244–252.
- Hanel A, Veldhuizen C, Carlberg C. Gene-Regulatory Potential of 25-Hydroxyvitamin D and D. Front Nutr. 2022; 9: 910601.
- Maj E, Filip-Psurska B, Milczarek M, et al. Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model. Int J Oncol. 2018; 52(2): 337–366.
- Feldman D, Krishnan AV, Swami S, et al. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014; 14(5): 342–357.
- Bhoora S, Pather Y, Marais S, et al. Cholecalciferol Inhibits Cell Growth and Induces Apoptosis in the CaSki Cell Line. Med Sci (Basel). 2020; 8(1).
- Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58(3): 621–681.
- Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22: 27–55.
- Cheng X, Liu D, Song H, et al. Overexpression of Kininogen-1 aggravates oxidative stress and mitochondrial dysfunction in DOX-induced cardiotoxicity. Biochem Biophys Res Commun. 2021; 550: 142–150.
- Sun Z, Zhou D, Yang J, et al. Doxorubicin promotes breast cancer cell migration and invasion via DCAF13. FEBS Open Bio. 2022; 12(1): 221–230.
- Estébanez N, Gómez-Acebo I, Palazuelos C, et al. Vitamin D exposure and Risk of Breast Cancer: a meta-analysis. Sci Rep. 2018; 8(1): 9039.
- Berger U, McClelland RA, Wilson P, et al. Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res. 1991; 51(1): 239–244.
- Buras RR, Schumaker LM, Davoodi F, et al. Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat. 1994; 31(2-3): 191–202.
- Voutsadakis IA. Vitamin D baseline levels at diagnosis of breast cancer: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2021; 14(1): 16–26.
- Saracligil B, Ozturk B, Unlu A, et al. The effect of vitamin D on MCF-7 breast cancer cell metabolism. Bratisl Lek Listy. 2017; 118(2): 101–106.
- Pilco-Ferreto N, Calaf GM. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol. 2016; 49(2): 753–762.
- Marques LA, Semprebon SC, Biazi BI, et al. Vitamin D and Salinomycin synergy in MCF-7 cells cause cell death via endoplasmic reticulum stress in monolayer and 3D cell culture. Toxicol Appl Pharmacol. 2022; 452: 116178.
- Lee KJ, Wright G, Bryant H, et al. Cytoprotective Effect of Vitamin D on Doxorubicin-Induced Cardiac Toxicity in Triple Negative Breast Cancer. Int J Mol Sci. 2021; 22(14).
- Dziuba I, Gawel AM, Tyrna P, et al. Homotypic Entosis as a Potential Novel Diagnostic Marker in Breast Cancer. Int J Mol Sci. 2023; 24(7).
- Durgan J, Tseng YY, Hamann JC, et al. Mitosis can drive cell cannibalism through entosis. Elife. 2017; 6.
- Liu J, Wang L, Zhang Y, et al. Induction of entosis in prostate cancer cells by nintedanib and its therapeutic implications. Oncol Lett. 2019; 17(3): 3151–3162.
- Mlynarczuk-Bialy I, Dziuba I, Sarnecka A, et al. Entosis: From Cell Biology to Clinical Cancer Pathology. Cancers (Basel). 2020; 12(9).
- Khalkar P, Díaz-Argelich N, Antonio Palop J, et al. Novel Methylselenoesters Induce Programed Cell Death via Entosis in Pancreatic Cancer Cells. Int J Mol Sci. 2018; 19(10).
- Su Y, Ren He, Tang M, et al. Role and dynamics of vacuolar pH during cell-in-cell mediated death. Cell Death Dis. 2021; 12(1): 119.